Conference Day 2

8:25 am Chair’s Opening Remarks

8:30 am Using Advanced Analytics & Digital Technological Capabilities to Support Patient Engagement in a New Digital World, from Diagnostic to Holistic Care

  • Roberto Araujo Head of Global Evidence Generation Strategy & Rare Diseases, Sanofi

Synopsis

  • Importance of validating and scaling AI, Machine Learning, Large Language Models and Remote Data Capture
  • How can these tools be used to maximize patient identification and engagement?
  • Case-study based insights from recent experience

9:00 am HEOR to HERO: Successfully Leveraging Comprehensive Real-World Data from Payers

Synopsis

  • Understand the importance of commercial, Medicare and Medicaid claims data in combination
  • Explore techniques to better access patient outcomes
  • Discover more accurate cost data to achieve formulary adoption

9:30 am Strategies to Ensure that RWE Generated Through AI/ML is Fit-For-Purpose In Accurately Addressing Scientific Research Questions

  • Mawuli Nyaku Strategy Head, Immunology and Communicable Diseases, Data Science & Digital Health, JNJ Innovative Medicine

Synopsis

  • Articulate the differences between technical and subject-matter expertise
  • Operationalize technical and subject-matter gating from project conception through completion
  • Opportunities to bridge the gap between technical and subject-matter expertise

10:00 am Considerations of Clinical Validation of AI Algorithms With Real World Data

  • Yong Chen Senior Director, Real World Evidence, Oncology, Pfizer

Synopsis

  • Highlighting the importance of optimizing AI algorithm development in RWD
  • Current challenges of prospective clinical validation of AI algorithm
  • Case study-based insights into how clinical validation process can be accelerated using RWD

10:30 am Morning Break & Networking Coffee

11:30 am Optimizing Generative AI for the Pharma Industry

  • Haoda Fu Associate Vice President - Enterprise Lead Machine Learning & AI, Eli Lilly & Co.

Synopsis

  • Leveraging generative AI to maximize its utility for real world evidence
  • Current challenges being faced with applying generative AI
  • Case-study based actionable insights to utilize generative AI more effectively

11:30 am Panel Discussion Reserved for Point Click Care

12:30 pm Leveraging RWD to Accelerate Clinical Development & Market Access

  • Hairong Xu Executive Director - Global Medical Affairs & Clinical Development, Kite Pharma Inc

Synopsis

  • Importance of accelerating clinical development
  • Current challenges faced by the industry which are acting as barriers to accelerating clinical development
  • Case-study based insights to showcase how this acceleration can be actioned

1:00 pm Lunch & Networking

2:00 pm Promoting Democrative Data: Leveraging Gen-AI, NLP tools to Strengthen Cross-Functional Relationships Across RWE Stakeholders

  • Lucas Oliveira Director, Real World Evidence & Strategy, Chiesi Inc.

Synopsis

  • Importance of having real-world data that can be interpreted across different teams
  • Utilizing AI as a tool to enhance real world data
  • How data democratization can be implemented in a cross-functional team

Strategies to Enhance Cross Functional Collaborations to Optimize Real World Data Utility

2:30 pm Panel: Developing an Internal Centralized Data Quality Check Department to Minimize Data Inefficiencies & Maximize Data Standardisation to Ensure Real-World Data Quality is Controlled from Initial Stages

  • Barry Grau Senior Manager - Real World Analytics, Vertex Pharmaceuticals
  • Joseph Cappelleri Executive Director - Biostatistics, Pfizer

Synopsis

  • Ensuring data is monitored from the very beginning to the final stages of analysis
  • What are the challenges of implementing stringent data checks
  • Where do most data inefficiencies arise from and how can this be tackled?

3:00 pm MDV Data in Japan

3:10 pm Leveraging Tokenization in the Context of Post-Authorization Safety Studies- Are We There Yet?

  • Daina Esposito Executive Director, Global Safety Epidemiology, Real World Evidence, Moderna

Synopsis

  • The promise of tokenization to enhance size, speed, and quality of RWE
  • Challenges faced in post-marketing tokenization, and tools to overcome them
  • Case study-based insights 

3:40 pm Ensuring Access to Innovative Therapies: Can or Should Medical Affairs Lead this Early Conversation

  • Siddharth Jain Director - Medical, Global Medical, Lysosomal Storage Diseases Lead, Takeda

Synopsis

  • Explore the significance of developing a tailored (RWE) strategy early in the launch planning process and the impact of early stakeholder conversations in shaping the RWE strategy
  • Highlight the pivotal role of Medical Affairs leadership in elevating the voice of patients and embrace patient reported outcome measures (PROMs) to enhance access outcomes
  • Delve into the importance of funnelling field insights to develop optimal objection handlers and establish the right value-based agreement strategy

4:10 pm Maximizing Collaboration: Building Effective Strategic Partnerships in an Evolving Healthcare and Data Ecosystem

  • Witney Baah Associate Director, Real World Value & Evidence, Partnerships, Data & Platforms, Johnson & Johnson

Synopsis

  • Building Robust Strategic Partnerships: Emphasizing the critical role of establishing strong internal and external partnerships to drive innovation and enhance real-world evidence generation
  • Overcoming Collaboration Challenges: Addressing common challenges such as differing organizational dynamics, goals, and resources
  • Optimizing Relationships through Case Studies: Sharing insights from real-world case studies that demonstrate best practices for optimizing strategic partnerships

4:40 pm Chair’s Closing Remarks & End of Summit